Seagen Founder Clay Siegall Named CEO of Purdue Spinout Morphimmune After Resigning in 2023

Clay Siegall, founder and former CEO of Seagen, has returned to biotech as CEO and president of Morphimmune, a Purdue University spinout relocating to Seattle. This move follows his resignation from Seagen in May 2023 and precedes Pfizer's planned $43 billion acquisition of Seagen.

More: GeekWire

No comments yet.